Progress report on the stimulant-depressant abuse liability evaluation project.

The laboratories reported data on CPDD 1 that was indeed very similar to that of their direct or historical controls for diazepam. It is clear that the antagonists used in the program will reverse only a benzodiazepine-induced behavioral effect. The data on bromazepam suggest a very similar pattern and potency for this benzodiazepine compared to diazepam.